INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE

Scope & Guideline

Navigating the Future of Respiratory Health

Introduction

Welcome to the INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageMulti-Language
ISSN1027-3719
PublisherINT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)
Support Open AccessNo
CountryFrance
TypeJournal
Convergefrom 1997 to 2024
AbbreviationINT J TUBERC LUNG D / Int. J. Tuberc. Lung Dis.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address68 BOULEVARD SAINT-MICHEL, 75006 PARIS, FRANCE

Aims and Scopes

The INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE focuses on advancing the understanding, diagnosis, treatment, and prevention of tuberculosis (TB) and related lung diseases. The journal aims to publish high-quality research that informs clinical practice and public health policy, especially in low- and middle-income countries where TB burden remains high.
  1. Tuberculosis Epidemiology and Public Health:
    Research on the epidemiology of tuberculosis, including trends, risk factors, and the impact of socio-economic and environmental determinants on TB transmission and outcomes.
  2. Diagnostic Innovations:
    Studies focusing on the development and evaluation of new diagnostic tools and methods for TB detection, including molecular techniques, imaging modalities, and point-of-care tests.
  3. Treatment Strategies and Drug Resistance:
    Clinical trials and observational studies evaluating treatment regimens for drug-susceptible and multidrug-resistant TB, including pharmacokinetics, drug interactions, and therapeutic monitoring.
  4. Comorbidities and TB:
    Research examining the interactions between TB and other diseases, particularly HIV, diabetes, and respiratory conditions, and their implications for treatment and management.
  5. Post-TB Health and Quality of Life:
    Investigations into the long-term health effects following TB treatment, including the burden of post-TB lung disease, quality of life assessments, and rehabilitation strategies.
  6. Public Health Interventions and Policy:
    Studies assessing the effectiveness of public health interventions, screening programs, and policy initiatives aimed at TB prevention and control.
Recent publications in the journal have highlighted several trending and emerging themes that are gaining attention within the field of tuberculosis and lung disease research. These themes reflect the evolving landscape of TB research, especially in the context of global health challenges.
  1. Impact of COVID-19 on TB Care:
    The intersection of TB and COVID-19 has emerged as a significant theme, with research exploring the effects of the pandemic on TB diagnosis, treatment, and healthcare delivery.
  2. Digital Health and Technology in TB Management:
    There is a growing focus on the use of digital technologies and telemedicine for TB management, including adherence monitoring, virtual consultations, and data management systems.
  3. Health Systems Strengthening and TB Services:
    Emerging studies are increasingly addressing the strengthening of health systems to improve TB care delivery, especially in low-resource settings, emphasizing integrated approaches to health services.
  4. Social Determinants of Health and TB:
    Research exploring the social determinants of health, including stigma, economic factors, and healthcare access, is gaining traction as a critical area for understanding TB epidemiology and outcomes.
  5. Innovative Diagnostic Approaches:
    A trend towards innovative diagnostic methods, including the use of artificial intelligence and machine learning in TB detection and management, is becoming prominent.

Declining or Waning

While the journal continues to cover a broad range of topics related to tuberculosis and lung disease, certain themes appear to be declining in prominence based on recent publications. This may reflect shifts in research focus or changes in public health priorities.
  1. Historical Perspectives on TB:
    Research focusing on historical trends and perspectives of tuberculosis, such as epidemiological studies from past decades, appears to be less frequent, indicating a shift towards contemporary issues.
  2. Basic Science Research:
    There seems to be a decline in purely laboratory-based studies related to the basic science of TB pathogens, as the focus shifts towards clinical applications and translational research.
  3. Non-Communicable Diseases and TB:
    While the intersection of TB with non-communicable diseases (NCDs) has been a topic of interest, it appears to be waning, possibly due to a greater emphasis on direct TB-related issues and immediate public health challenges.

Similar Journals

International Journal of Mycobacteriology

Unveiling the complexities of infectious diseases.
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 2212-5531Frequency: 4 issues/year

International Journal of Mycobacteriology is a peer-reviewed, open-access journal published by Wolters Kluwer Medknow Publications that specializes in the field of infectious diseases with a particular emphasis on mycobacterial research. Since its inception in 2012, this journal has emerged as a vital resource for researchers, healthcare professionals, and students aimed at advancing understanding and treatment of mycobacterial infections, including tuberculosis. With the journal being indexed in Scopus and holding a Q3 ranking in both Infectious Diseases and Microbiology (medical) for 2023, it reflects a substantial contribution to scholarly discourse in these domains, despite its current ranking positioning. Authors and readers benefit from the open access model, ensuring widespread dissemination of research findings and fostering collaboration across the global health community. Located in Mumbai, India, the journal continues to thrive with a commitment to quality research and innovation, welcoming contributions that further the exploration of mycobacteriology throughout the converged years from 2012 to 2024.

Tuberculosis and Respiratory Diseases

Fostering innovation in pulmonary medicine.
Publisher: THE KOREAN ACAD TUBERCULOSIS & RESPIRATORY DISEASESISSN: 1738-3536Frequency: 4 issues/year

Tuberculosis and Respiratory Diseases is a leading open-access journal published by THE KOREAN ACADEMY OF TUBERCULOSIS & RESPIRATORY DISEASES, dedicated to disseminating knowledge in the fields of infectious diseases and pulmonary medicine. Since its inception in 1980, the journal has undergone significant growth, currently recognized in the elite Q2 category for both Infectious Diseases and Pulmonary and Respiratory Medicine as of 2023. With an impact factor reflecting its esteemed position—ranked 52nd in its category—it serves as a vital resource for researchers and healthcare professionals seeking cutting-edge insights, studies, and advancements in the management and treatment of respiratory diseases, particularly tuberculosis. The journal is committed to providing open access to its content since 2013, ensuring that critical research is available to scholars worldwide, fostering collaboration and innovation in the global fight against respiratory illnesses.

Infection and Drug Resistance

Championing open access for groundbreaking research in infection control.
Publisher: DOVE MEDICAL PRESS LTDISSN: 1178-6973Frequency: 1 issue/year

Infection and Drug Resistance, published by DOVE MEDICAL PRESS LTD, is a leading open-access journal dedicated to the critical fields of infectious diseases and pharmacology. Since its establishment in 2008, this journal has emerged as a vital resource for researchers, professionals, and students alike, offering thorough insights into the mechanisms of drug resistance and the effectiveness of various therapeutic interventions. With an impressive 2023 impact factor placing it in the Q2 category across multiple relevant disciplines, including Infectious Diseases and Pharmacology, it serves as a significant platform for high-quality research dissemination. Infection and Drug Resistance aims to foster a deeper understanding of the evolving challenges in managing infectious diseases and enhancing drug efficacy, contributing to the global discourse on public health. The journal's commitment to open access ensures that vital knowledge is readily available to promote broader scholarly engagement and innovation.

Cyprus Journal of Medical Sciences

Championing impactful research for the medical community.
Publisher: GALENOS PUBL HOUSEISSN: 2149-7893Frequency: 6 issues/year

Welcome to the Cyprus Journal of Medical Sciences, a distinguished publication dedicated to the advancement of medical knowledge and research. Published by GALENOS PUBL HOUSE, this journal endeavors to uphold the highest standards of scientific inquiry in the medical field. With its ISSN 2149-7893 and E-ISSN 2536-507X, the journal serves as an essential resource for researchers, healthcare professionals, and students seeking to stay abreast of innovative findings and clinical practices. Although currently not listed under Open Access, this journal prioritizes rigorous peer review and the dissemination of impactful research aimed at driving improvements in medical science. The journal welcomes submissions that cover diverse areas within the medical realm, contributing to a more profound understanding of healthcare challenges and solutions. Join us in exploring the frontiers of medical sciences and contributing to a healthier future.

Lung Cancer Management

Unveiling the Latest Breakthroughs in Oncology
Publisher: FUTURE MEDICINE LTDISSN: 1758-1966Frequency: 4 issues/year

Lung Cancer Management, published by FUTURE MEDICINE LTD, is a premier academic journal dedicated to the evolving field of oncology and respiratory medicine. With an ISSN of 1758-1966 and an E-ISSN of 1758-1974, this journal offers a platform for the dissemination of cutting-edge research, clinical studies, and expert reviews, all focusing on the latest advances in lung cancer treatment and management. Despite being a relatively new entry since its inception in 2014 and achieving its converged years from 2020 to 2024, it has already established itself in the Q3 quartile for both oncology and pulmonary and respiratory medicine as of 2023, according to category quartiles rankings. With a Scopus ranking of #98 in the category of Pulmonary and Respiratory Medicine and #266 in Oncology, the journal reflects a commitment to quality and relevance in its content. Although it does not offer open access, it remains a crucial resource for researchers, clinicians, and students seeking to stay informed about the latest developments and practical approaches in lung cancer management. The journal is accessible from its base in the United Kingdom, at UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ensuring that it caters to a global audience eager to explore and contribute to this vital field of medicine.

Pulmonology

Elevating knowledge and practice in pulmonary medicine.
Publisher: ELSEVIERISSN: 2531-0437Frequency: 6 issues/year

Pulmonology, an esteemed journal published by Elsevier, serves as a vital platform for advancing knowledge in the field of Pulmonary and Respiratory Medicine. Since its transition to Open Access in 2018, this journal has successfully fostered a global readership, allowing for unrestricted dissemination of cutting-edge research. With an impressive Scopus ranking of #8 out of 155 in its category and a notable 2023 Q1 status, Pulmonology consistently showcases high-quality studies and reviews that contribute to the understanding and treatment of respiratory disorders. Authors and readers alike benefit from its commitment to publish influential research that addresses contemporary challenges in lung health. By bridging the gap between theory and clinical practice, the journal paves the way for innovative practices in pulmonology, making it an indispensable resource for researchers, healthcare professionals, and students interested in this dynamic field.

Eurasian Journal of Pulmonology

Pioneering open access to vital pulmonology knowledge.
Publisher: KARE PUBLISSN: 2148-3620Frequency: 3 issues/year

The Eurasian Journal of Pulmonology is a premier open access journal dedicated to advancing the field of respiratory medicine and thoracic diseases. Published by KARE PUBL since 1999, the journal serves as an invaluable platform for researchers, clinicians, and students, facilitating the dissemination of innovative research findings and clinical practices. With an emphasis on high-quality and peer-reviewed articles, it aims to foster collaboration and knowledge sharing among professionals in the pulmonology community. Although the journal’s precise impact factor is currently not specified, its commitment to openness and accessibility ensures a broad reach and engagement with vital research, making it a critical resource for those in the academic and medical fields. The journal is based in Istanbul, Turkiye, further enriching its contributions to the Eurasian medical landscape and global health discourse.

RESPIROLOGY

Elevating Respiratory Health Through Research
Publisher: WILEYISSN: 1323-7799Frequency: 12 issues/year

RESPIROLOGY is a prestigious academic journal that focuses on the field of Pulmonary and Respiratory Medicine, publishing high-quality research and comprehensive reviews that contribute significantly to the understanding and management of respiratory health. As a distinguished publication of WILEY, it has established a strong presence in the academic world with an impressive impact factor and ranked in the Q1 category, recognized for its influence and innovation in the field. RESPIROLOGY is committed to disseminating cutting-edge research from 1996 through 2024, appearing regularly in SCOPUS with a rank of #14 out of 155, placing it in the rarefied 91st percentile among its peers. The journal invites contributions from researchers, professionals, and students, fostering a collaborative space for advancing knowledge in pulmonary medicine. Although it does not offer open access, its readership spans globally, indicating the high regard in which it is held within the scientific community.

THORAX

Exploring the frontiers of respiratory medicine.
Publisher: BMJ PUBLISHING GROUPISSN: 0040-6376Frequency: 12 issues/year

THORAX is a premier academic journal dedicated to advancing knowledge in the field of Pulmonary and Respiratory Medicine. Published by the esteemed BMJ Publishing Group in the United Kingdom, this journal has been a pivotal resource for researchers and clinicians since its inception in 1946. With a remarkable ranking of #6 out of 155 in its category, THORAX holds a prestigious position within the top 4% of its field, as indicated by its 2023 Q1 quartile classification and a strong Scopus ranking. The journal focuses on publishing high-quality research, reviews, and clinical studies that are essential for understanding respiratory diseases and their management. Although it is not an open-access journal, THORAX provides vital contributions to the academic community, fostering dialogue and innovation in pulmonary medicine. As it approaches its converged years, concluding in 2024, researchers, professionals, and students are encouraged to explore its rich repository of knowledge, while engaging with the most current advancements in the field.

RESPIRATION

Advancing the Frontiers of Pulmonary Medicine
Publisher: KARGERISSN: 0025-7931Frequency: 12 issues/year

RESPIRATION is a prestigious journal dedicated to advancing knowledge in the field of Pulmonary and Respiratory Medicine, with a commitment to publishing high-quality, peer-reviewed research. Established in 1944 and published by KARGER in Switzerland, this journal has maintained an exemplary impact within the scientific community, currently holding a Q1 ranking in the 2023 category for Pulmonary and Respiratory Medicine, placing it among the top 18% of journals in its field. With an ISSN of 0025-7931 and an E-ISSN of 1423-0356, RESPIRATION provides a platform for researchers and professionals to disseminate original studies, reviews, and clinical cases that shape contemporary understanding and treatment of respiratory diseases. The journal's rigorous standards for publication ensure that it remains a vital resource for the latest innovations and findings. As part of its mission, RESPIRATION seeks to bridge the gap between clinical practice and research, fostering multidisciplinary collaboration and enhancing patient outcomes. The journal is readily accessible, ensuring that vital research reaches a broad audience of healthcare professionals and academic scholars globally.